Biomerica has secured its first commercial order for its Helicobacter pylori diagnostic stool antigen test, Hp Detect™, from one of Europe’s largest clinical laboratory chains. This initial shipment targets the United Kingdom market, where the test received UK Medicines and Healthcare products Regulatory Agency approval in February 2026.

The laboratory chain’s extensive network across multiple European countries makes it a strategic reference account for Biomerica, offering potential visibility among key healthcare providers. Integration of Hp Detect™ into this customer’s routine testing workflow is expected to pave the way for broader adoption across the EU laboratory channel.

H. pylori infection affects an estimated 45% of the population across Europe’s five largest countries and is designated a Class 1 carcinogen. In the United Kingdom, National Health Service guidelines recommend routine testing and treatment for H. pylori in patients with gastrointestinal symptoms, supporting steady diagnostic demand.

Biomerica anticipates this initial order will lead to recurring purchases as Hp Detect™ becomes embedded in the laboratory chain’s operations. The company plans to leverage this reference relationship to negotiate additional distribution agreements in other European markets and in the United States, driving future revenue growth.